ClinicalTrials.Veeva

Menu

Furosemide Stress Test to Predict Successful Liberation From RRT (FST-RRT)

V

Vaud University Hospital Center

Status

Completed

Conditions

Acute Kidney Injury

Treatments

Drug: Furosemide stress test

Study type

Observational

Funder types

Other

Identifiers

NCT05612490
2022-01826

Details and patient eligibility

About

The proposed study will evaluate if a standardised dose of furosemide administered in the 12 hours after RRT liberation can predict successful liberation in critically ill patients. The dose that will be administered is in accordance with the prescribing information.

Full description

Response to furosemide administration is commonly used in clinical practice to assess a patient's potential for RRT liberation. However, this administration is not standardized and practices varies greatly. Rapid recognition of unsuccessful RRT liberation is crucial to avoid further complications such as fluid overload or acid-base and electrolyte disorders. The FST corresponds to the intravenous administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. FST is able to predict progression from AKI stage I and II to stage III with a high sensitivity (87.1%) and specificity (84.1%), area under the ROC curve 0.87. However, the ability of FST to predict RRT liberation has never been formally assessed.

Enrollment

52 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Receiving continuous or intermittent RRT for AKI
  • Having an indwelling urinary catheter
  • Clinical decision by physician in charge to attempt RRT liberation
  • lnformed consent signed by the patient himself / legal representative or authorization received from independent physician

Exclusion criteria

  • Electrolyte disturbances or hemodynamic instability precluding the use of furosemide (sodium > 155 mmol/L and/or potassium < 3.0 mmol/L and/or metabolic alkalosis > 7.50 and/or mean arterial pressure < 60 mmHg)
  • Known furosemide allergy
  • Urine output ≥ 100 mL/h for at least two hours
  • Recent (< 24 hours) FST
  • Known end-stage chronic renal disease at ICU admission
  • Withdrawal of life support decision taken before inclusion
  • Patient already participating in conflicting research study
  • Patient having already participated in this current study
  • Any other contraindication of furosemide

Trial design

52 participants in 1 patient group

Critically ill patients undergoing RRT
Description:
Patients admitted to participating ICU and receiving renal replacement therapy.
Treatment:
Drug: Furosemide stress test

Trial contacts and locations

1

Loading...

Central trial contact

Antoine schneider, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems